Clinical Trial Update: Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and pharmacokinetics of NNC 0129-0000-1003 in subjects with Haemophilia A has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• NNC 0129-0000-1003

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED